| Name | Title | Contact Details |
|---|
TruStone Financial Credit Union is a member-owned financial cooperative based in Plymouth, Minnesota. Founded in 1939 by eight educators, it has grown to become Minnesota’s second-largest credit union, serving members across Minnesota and Wisconsin through 13 branches. The credit union emphasizes financial education, reflecting its origins as a teachers credit union, and operates under a "For Life" philosophy that prioritizes long-term relationships with members and community prosperity. TruStone offers a range of services, including digital banking for account management, loans for auto, mortgage, and personal needs, as well as credit cards and investment products. It also provides business solutions such as commercial lending and business account services. The TruStone Foundation promotes financial literacy through partnerships and scholarship programs, supporting youth education in the community. The credit union continues to grow through strategic mergers and technological investments, enhancing its member services and operational efficiency.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
IMCD Group is a global distributor of specialty chemicals and ingredients, headquartered in Rotterdam, Netherlands. Founded in 1995, the company is listed on the Amsterdam stock exchange and celebrated its 25th anniversary in 2020. IMCD specializes in serving various industries, including pharmaceuticals, food, personal care, coatings, and lubricants, providing formulatory solutions tailored to customer needs. The company has expanded its operations internationally, with significant growth in the Americas, including the establishment of IMCD US in 2015. IMCD Group generates approximately $4.7 billion in revenue and employs around 3,570 people worldwide. Known for its innovative approach and minimal corporate bureaucracy, IMCD maintains strong partnerships with a diverse range of suppliers and customers, from small manufacturers to large corporations.
In 2015, an important group of investors alongside a group of experienced professionals in the Reinsurance industry, acquired a majority interest in MBI Americas. Now, XS Global, a well-known regional MGA and Coverholder at Lloyds. The groups footprint and ambitions now encompass the underwriting space, utilizing strong synergies that exist between the groups core business strategy. Our unique structure provides us opportunities to deploy targeted reinsurance capacity both directly to corporates and to retail brokers via expert and locally based underwriters. We are proud to say we invest in talent and our team has proven skills, excellent access, and a proven track record for underwriting profitable business in the Latin America region and beyond.